Dr. Ilango Subramanian is President of Odin Pharmaceuticals. In this role, Dr. Subramanian is responsible for R&D, Operations, and overall administration of the company. Prior to joining the Odin, Dr.Subramanian held a number of leadership positions at Novel Laboratories and GAVIS Pharmaceuticals from 2010 to 2015 as Vice President, responsible for Corporate Development, Biopharmaceutics, Medical Affairs, and Project Management. As a cross-functional executive, Dr.Subramanian coordinated the Novel and GAVIS teams in development of over 100 drug products and commercialization of 25 drug products as well as creating strategic development alliances with R&D organizations in softgel and transdermal drug technologies. Prior to this, Dr.Subramanian served as a Project Manager at Publicis Healthcare and a Consultant for BGB Healthcare Group. Dr. Subramanian received a Doctor of Pharmacy from Rutgers University Ernest Mario School of Pharmacy in 2009 and a Masters in Business Administration from New York University Stern School of Business in 2014. He is a registered pharmacist in New Jersey.
Chief Financial Officer
Arshad Kagalwalla is an accounting executive with over 20 years of experience in Finance & Accounting and 15 years in the generic pharmaceutical industry. Mr. Kagalwalla joined Odin Pharmaceuticals in 2018 as CFO and is responsible for all Accounting and Finance functions of the company, including financial planning and analysis, budgeting and forecasting, taxation and revenue management. Prior to this, Mr.Kagalwalla served as CFO at Somerset Therapeutics from 2016. Prior to joining Somerset, Arshad was Head of Finance and Accounting at Novel Laboratories and GAVIS Pharmaceuticals and has served as an accounting executive for Par Pharmaceuticals and Kali Laboratories. Mr.Kagalwalla receiving a CPA in 2004 following work as a public accountant. Mr.Kagalwalla has a Bachelors in Commerce and is a Chartered Accountant in India.
Vice President, Quality & Regulatory Affairs
Scott Talbot joined Odin in June of 2019 as the Vice President of Quality Assurance & Regulatory Affairs. In this role, Mr.Talbot manages all regulatory and quality operations within the company. Mr.Talbot brings to Odin over 30 years of quality and compliance experience with extensive expertise in sterile facility compliance with the FDA. Before joining Odin, Scott served as Vice President of Quality and Regulatory Affairs for Slayback Pharma. Prior to Slayback, Mr.Talbot held management positions at Baxter Healthcare, Bausch & Lomb Pharmaceuticals, Teva, and Actavis. He has worked closely with FDA district offices in Puerto Rico, Florida, Kansas, and New Jersey on behalf of facilities in those districts, successfully resolving issues raised by FDA warning letters sent to these facilities. Scott holds bachelor’s degrees in biology and chemistry from Illinois State University.
Vice President, Product Development
Dr. Julianne Berry joined Odin in 2021 as Vice President of Respiratory Product Development with the role of establishing Odin’s brand and generic respiratory programs from an early stage through commercialization. Dr. Berry has over 30 years end to end development of the brand and generic respiratory and specialty products for US and Global Markets and is credited with the development of key marketed metered dose inhalers, nasal sprays, dry powder inhalers and nebulizers. Prior to joining Odin, Dr. Berry has held numerous executive and leadership positions at Schering-Plough, Merck, Novel, Lupin and Glenmark. Dr. Berry has been at the forefront of advancing respiratory science with authorship of numerous publications, ownership of critical drug delivery patents and leadership in International Industry Consortium working groups. Dr. Berry obtained a Post-Doctoral Degree in Pharmaceutical Chemistry from The University of Kansas, a Ph.D. degree in Physical Organic Chemistry from The University of California at Santa Cruz and a B.A. degree in Chemistry from Colgate University.
Analytical Research and Quality Executive
Swapan directs the company’s analytical services and quality control departments. He has experience in both day-to-day management and long-term process improvement, and bears the significant responsibility of ensuring compliance with regulatory, health, safety, and environmental guidelines, policies, and procedures.
Roy has more than 30 years experience in the pharmaceutical industry and has leveraged his technical expertise and management skills at many successful generic pharmaceutical companies including Actavis, Par Pharmaceuticals, Zenith/Goldline Pharmaceuticals and Purepac Pharmaceutical Co. An industry veteran, Roy has developed analytic tests and quality systems for over one hundred ANDA submissions. Roy holds a master’s of business administration, focusing on general management, from Rutgers University.